By identifying isoform-dependent interfaces and predicted allosteric modulation within D2R/GHSR1a heteromers, the study provides a mechanistic framework that could be exploited to design heteromer- or isoform-selective therapeutics for Parkinson's disease, though experimental validation is required.

It shows peripheral monocyte GCase reflects GBA1 genotype but is unlikely to be a useful peripheral biomarker of cognitive decline or central cholinergic dysfunction, steering therapeutic biomarker efforts toward central measures or alternative targets for GCase-modulating interventions.

NOS offers a practical, scalable olfactory screening method to identify prodromal PD and enrich cohorts for early‑intervention trials and biomarker studies, aiding translational research and trial recruitment even though it does not report new mechanistic or therapeutic interventions.

It highlights glial circadian regulation of neuroinflammation, oxidative stress, and sleep-related processes that are relevant to Parkinson's therapeutic timing and glia-targeted strategies, but remains a broad review with limited direct, actionable targets for immediate drug discovery.

Relevant to Parkinson's for its focus on improving graft survival, modulating neuroinflammation/oxidative stress, and enabling organoid-based cell-replacement or disease-modeling approaches, but it is a conceptual review with limited actionable molecular targets or immediate therapeutic leads.

It highlights misregulated neuronal microexon splicing as a disease mechanism that could be targeted by splice-modulating therapies and may reveal mechanistic convergence across genetic movement disorders, though it has limited direct relevance to canonical Parkinson's disease pathways like…

Although it offers little mechanistic insight for Parkinson's drug discovery, the study reinforces the clinical efficacy of GPi neuromodulation in severe genetic dystonia and supports the translational relevance of basal ganglia DBS approaches across movement disorders.

While offering little in terms of PD-targeted mechanisms or therapeutic discovery, the study is clinically relevant because reduced antipsychotic use in patients with parkinsonism and the high psychotropic burden in DSD underscore medication-safety and symptom-management issues—and the need to…

This identifies a repurposing-ready compound that targets a mechanistically novel, upstream process (biomolecular condensation/LLPS) to prevent α‑syn aggregation, giving a tangible translational lead for PD therapy development pending in vivo efficacy and safety studies.

The study provides objective evidence that multidisciplinary in‑patient care improves motor outcomes and supports using instrumental measures for monitoring and payer justification, but it offers limited mechanistic insight or direct leads for therapeutic discovery.

Provides mechanistic and translationally relevant evidence that a nanoparticle combining enhanced brain delivery with ROS elimination and anti-neuroinflammatory effects can ameliorate PD phenotypes, highlighting a promising therapeutic strategy while raising important safety and manganese-toxicity…

By linking vesicle trafficking and immune alterations to specific, druggable-sounding genes (TRAPPC13, COPS5) this study highlights mechanistic hypotheses and patient stratification axes useful for therapeutic target prioritization and follow-up functional validation, though its translational…

This provides a peripheral, inflammation-related biomarker candidate reflecting impaired immunoregulatory capacity in advanced PD that could help stage disease or stratify patients for immune-modulatory approaches, albeit requiring validation and mechanistic follow-up.

Moderately relevant to Parkinson's research because it models how viral-triggered chronic neuroinflammation and neuron loss can drive lasting behavioral deficits and could be used to test anti-inflammatory or neuroprotective strategies, but it lacks PD-specific mechanisms (e.g., alpha-synuclein,…

The work links environmental manganese and viral infection to heightened hippocampal neuroinflammation relevant to PD-related cognitive decline, supporting inflammation as a potential intervention axis even though it lacks direct PD-specific mechanisms or therapeutic candidates.

This paper has minimal direct relevance to Parkinson's therapeutic discovery but highlights the need for accurate systemic diagnosis and multidisciplinary management of complex comorbidities, a tangential consideration for patient selection and safety in neurodegeneration clinical research.

By delivering a quantifiable, scalable preclinical model and objective behavioral readouts, the work enables circuit-level mechanistic studies and screening of interventions for PD visual hallucinations, increasing translational potential despite limited immediate molecular targets.

While not revealing molecular targets, the work highlights a measurable biomechanical biomarker (APA duration) and supports therapeutic strategies aimed at improving postural preparation and executive control (e.g., targeted rehabilitation or neuromodulation) to reduce freezing episodes.

Modulating peptide aggregation with electric fields is an intriguing, nonchemical approach that could conceivably be applied to reduce amyloid-like fibrillation (e.g., alpha-synuclein) relevant to Parkinson's, but this study uses artificial short peptides and lacks disease‑relevant proteins,…

Although it offers little direct mechanistic or druggable insight, the study highlights socioeconomic factors as important confounders for clinical outcomes, trial design, patient stratification, and non-pharmacologic interventions that can influence therapeutic development and access.